Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- INTT +2.9%
Other news:
- PCVX +51.7% (VAX-31 met all prespecified primary endpoints in the pivotal Phase 3 OPUS-1 trial and was well tolerated.)
- PTC +36.0% (Schneider Electric agreed to acquire PTC for $205 per share in cash, implying a roughly €21 billion enterprise value.)
- ALEC +34.3% (Licenses AL050 to Genentech for $100 million upfront and up to $1.17 billion in milestones plus royalties.)
- RXO +20.8% (Agreed to be acquired by C.H. Robinson for $5.8 billion, or an implied $30.25 per share.)
- TAVI +11.4% (Appointed Andrew Wiederhorn CEO and executive chairman and named Kenneth Kuick CFO, effective October 1.)
- RZLT +9.2% (FDA recommended requesting a Type B pre-BLA meeting for ersodetug in congenital hyperinsulinism after reviewing Phase 3 data.)
- ALVO +7.5% (FDA approved a second SIMLANDI production suite, effectively doubling Alvotech’s drug-substance manufacturing capacity for U.S. supply.)
- CBRS +4.7% (OpenAI CEO Sam Altman confirmed Cerebras is a close partner with deep engagement focused on advancing speed.)
- GEO +3.2% (Sold three Adelanto ICE facilities to DHS for $950 million and increased its buyback authorization to $1.25 billion.)
- AGEN +2.0% (Reports 48% estimated three-year survival for BOT+BAL in recurrent ovarian cancer, with no new safety signals.)
- VTRS +2.0% (Completed the TYRVAYA rights sale to Harrow for $30 million upfront and up to $70 million in milestones.)
- BKR +1.8% (Signed Venezuela gas-infrastructure alliance and separate MOU with New Stratus for future oil and gas development.)
- ETR +1.5% (Names David Borde president and CEO of Entergy Texas, effective Oct. 5.)
- RDW +1.5% (Wins follow-on Axiom Space contract to develop and deliver two solar array wings for its second station module.)
- TKNO +1.2% (Will exclusively manufacture and distribute PluriFreeze in U.S. and Canada as Pluristyx completes its FDA drug master file.)
- HAFN +1.2% (Issued 35.5 million shares after completing a previously announced equity offering raising about $300 million.)
- QCOM +1.0% (Will return to trial against Arm Holdings.)
- GMAB +1.0% (Reported Phase 1/2 Rina-S data showing a 45.9% response rate and 12.1-month median response duration.)